Kairos Venture Partners II, L.P. insider trades: Actuate Therapeutics (ACTU) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Kairos Venture Partners II, L.P. reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | ACTU | ↓ Sell | 280,000 | $5.80 | $1.6M | By Kairos Venture Partners II, L.P. | Jan 7, 2026 (2d) |
| Aug 14, 2024 | ACTU | ↓ Sell | 18,750 | $8.00 | $150K | By KVP II, L.P. | Aug 16, 2024 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ACTU insiders
Open-market trades in the last 12 months
About Kairos Venture Partners II, L.P.'s insider trades
Kairos Venture Partners II, L.P. is an insider at Actuate Therapeutics (ACTU). Since Aug 14, 2024, it has reported no open-market purchases and 2 sales worth $1.8M on SEC Form 4. In the last 12 months: 1 sale ($1.6M).
Its filings also include grants and awards (2 filings), conversions (1 filing), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ACTU insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.